Status:
COMPLETED
The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease
Lead Sponsor:
Forest Laboratories
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
Memory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate. Glutamate helps transmit messages between nerve cells...
Eligibility Criteria
Inclusion
- Clinical diagnosis of moderate to severe Alzheimer's disease;
- ambulatory patients
Exclusion
- folate deficiency;
- clinically significant central nervous system disease other than Alzheimer's disease;
- clinically significant pulmonary, gastrointestinal, renal, hepatic, endocrine or cardiovascular disease
Key Trial Info
Start Date :
March 1 2003
Trial Type :
INTERVENTIONAL
End Date :
March 1 2005
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00090116
Start Date
March 1 2003
End Date
March 1 2005
Last Update
March 5 2012
Active Locations (34)
Enter a location and click search to find clinical trials sorted by distance.
1
Pivotal Research Centers
Peoria, Arizona, United States, 85381
2
21st Century Neurology
Phoenix, Arizona, United States, 85013
3
Margolin Brain Institute
Fresno, California, United States, 93720
4
Pharmacology Research Institute
Northridge, California, United States, 91324